Literature DB >> 20215707

Advanced glycation end product-mediated matrix metallo-proteinase-9 and apoptosis via renin-angiotensin system in type 2 diabetes.

Toshiyuki Ishibashi1, Michiko Kawaguchi, Koichi Sugimoto, Hironori Uekita, Nobuo Sakamoto, Keiko Yokoyama, Yukio Maruyama, Yasuchika Takeishi.   

Abstract

AIM: Advanced glycation end products (AGE) play a key role in diabetic vascular complications, whereas matrix metalloproteinases (MMPs) and apoptosis contribute to plaque instability. This study was conducted to investigate the association of AGE-mediated MMP-9 and apoptosis with the renin-angiotensin system (RAS). We also examined the correlation between plasma HbA1c levels and plaque parameters.
METHODS: We used autopsy specimens from the aortae and coronary arteries of patients with or without diabetes (n=11, each group) for the immunohistochemistry of AGE, MMP-9, angiotensin-converting enzyme (ACE), and the receptor for AGE (RAGE). Apoptosis was determined by TUNEL staining.
RESULTS: The proportions of AGE accumulation, MMP-9 expression and apoptosis in intimal areas of both aortic and coronary specimens of diabetics were greater than in nondiabetics. MMP-9 expression and apoptosis were correlated with AGE accumulation. RAGE expression was significantly increased in diabetic specimens compared to nondiabetes. Interestingly, the expression of ACE in diabetic specimens was increased and also correlated with AGE accumulation, RAGE expression, MMP-9 expression, and apoptosis in all specimens from diabetics and nondiabetics. Plasma levels of HbA1c were linearly correlated with AGE accumulation, MMP-9, apoptosis, and ACE expression.
CONCLUSION: The present study shows that AGE/RAGE-related MMP-9 expression and apoptosis were correlated with ACE expression in diabetic plaques and that RAS may be involved in AGE-dependent diabetic vascular complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215707     DOI: 10.5551/jat.3590

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  6 in total

1.  Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.

Authors:  R Ning; M Chopp; T Yan; A Zacharek; C Zhang; C Roberts; X Cui; M Lu; J Chen
Journal:  Neuroscience       Date:  2012-07-20       Impact factor: 3.590

2.  High serum level of matrix metalloproteinase 9 and promoter polymorphism - 1562 C:T as a new risk factor for metabolic syndrome.

Authors:  Suraj S Yadav; Raju K Mandal; Manish K Singh; Archna Verma; Pradeep Dwivedi; Rishi Sethi; Kauser Usman; Sanjay Khattri
Journal:  DNA Cell Biol       Date:  2014-09-11       Impact factor: 3.311

Review 3.  Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.

Authors:  Jack Cheng; Hsin-Ping Liu; Cheng-Chun Lee; Mei-Ying Chen; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  Neurol Sci       Date:  2017-11-04       Impact factor: 3.307

4.  RAGE and tobacco smoke: insights into modeling chronic obstructive pulmonary disease.

Authors:  Adam B Robinson; Jeffrey A Stogsdill; Joshua B Lewis; Tyler T Wood; Paul R Reynolds
Journal:  Front Physiol       Date:  2012-07-25       Impact factor: 4.566

Review 5.  Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.

Authors:  Kiyoshi Kikuchi; Salunya Tancharoen; Takashi Ito; Yoko Morimoto-Yamashita; Naoki Miura; Ko-ichi Kawahara; Ikuro Maruyama; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

6.  Effects of reduced β2-glycoprotein I on the expression of aortic matrix metalloproteinases and tissue inhibitor matrix metalloproteinases in diabetic mice.

Authors:  Jun Xu; Penghua Wang; Tong Wang; Meijun Wang; Sisi Chen; Pei Yu; Demin Yu
Journal:  BMC Cardiovasc Disord       Date:  2014-09-10       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.